Janus Capital Management LLC boosted its position in Alkermes PLC (NASDAQ:ALKS) by 220.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,658,928 shares of the company’s stock after buying an additional 1,140,555 shares during the period. Janus Capital Management LLC’s holdings in Alkermes PLC were worth $97,045,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its position in Alkermes PLC by 0.6% in the first quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock worth $415,000 after buying an additional 42 shares in the last quarter. Greenwood Capital Associates LLC increased its position in Alkermes PLC by 2.4% in the first quarter. Greenwood Capital Associates LLC now owns 3,729 shares of the company’s stock worth $218,000 after buying an additional 89 shares in the last quarter. Fiera Capital Corp increased its position in Alkermes PLC by 2.1% in the fourth quarter. Fiera Capital Corp now owns 5,516 shares of the company’s stock worth $307,000 after buying an additional 116 shares in the last quarter. Mn Services Vermogensbeheer B.V. increased its position in Alkermes PLC by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after buying an additional 224 shares in the last quarter. Finally, M&T Bank Corp increased its position in Alkermes PLC by 4.0% in the first quarter. M&T Bank Corp now owns 6,935 shares of the company’s stock worth $405,000 after buying an additional 266 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.
Shares of Alkermes PLC (NASDAQ ALKS) traded down 1.57% during trading on Monday, reaching $57.55. The company’s stock had a trading volume of 187,958 shares. The stock’s 50 day moving average price is $58.54 and its 200 day moving average price is $57.19. Alkermes PLC has a 52 week low of $39.65 and a 52 week high of $63.40. The company’s market cap is $8.82 billion.
Alkermes PLC (NASDAQ:ALKS) last posted its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.07. The business had revenue of $191.80 million for the quarter, compared to analyst estimates of $195.79 million. Alkermes PLC had a negative return on equity of 9.76% and a negative net margin of 25.61%. The firm’s revenue was up 22.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. Equities research analysts predict that Alkermes PLC will post ($0.04) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Janus Capital Management LLC Boosts Stake in Alkermes PLC (ALKS)” was first reported by Mideast Time and is owned by of Mideast Time. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.mideasttime.com/janus-capital-management-llc-boosts-stake-in-alkermes-plc-alks/1811705.html.
A number of research firms recently commented on ALKS. ValuEngine upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Morgan Stanley restated an “equal weight” rating and issued a $62.00 price objective on shares of Alkermes PLC in a report on Monday, April 24th. Jefferies Group LLC restated a “buy” rating and issued a $70.00 price objective on shares of Alkermes PLC in a report on Monday, April 3rd. Leerink Swann downgraded Alkermes PLC from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $68.00 to $61.00 in a report on Tuesday, June 13th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $51.00 price objective on shares of Alkermes PLC in a report on Thursday, March 16th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Alkermes PLC currently has an average rating of “Hold” and a consensus price target of $63.10.
In related news, insider Shane Cooke sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $60.33, for a total transaction of $603,300.00. Following the transaction, the insider now directly owns 84,708 shares of the company’s stock, valued at approximately $5,110,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $58.19, for a total value of $2,909,500.00. Following the transaction, the director now directly owns 680,406 shares in the company, valued at $39,592,825.14. The disclosure for this sale can be found here. Insiders have sold a total of 166,570 shares of company stock worth $9,642,375 over the last three months. 5.34% of the stock is owned by insiders.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.